Neurology Central

Aβ immunotherapy for Alzheimer’s disease: where are we?


Alzheimer’s disease (AD) was implicated in most of the estimated 46.8 million worldwide dementia cases in 2015, with projections set to almost triple by 2050 [1]. Because current therapies are focused on ameliorating AD symptoms instead of targeting the underlying causes of the disease, it is necessary to develop disease-modifying therapies.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.